Back

Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial.

31 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Giulia Ferrannini

Karolinska Institute, Stockholm (Sweden)

7 More presentations in this session

Presentation thumbnail
Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis
Professor H. Colhoun (Edinburgh, GB)
Abstract Slides Video
Presentation thumbnail
Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition
Doctor H. Kondo (Yufu City, JP)
Abstract Slides Video
Presentation thumbnail
Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME
Professor S. Verma (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial
Professor H. Heerspink (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
The effects of empagliflozin on arterial stiffness, endothelial function and ventriculoarterial coupling in type 2 diabetes mellitus: 1 year follow up
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

The Event

Event poster

ESC Congress 2020

31 August 2020 08:30 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources